Join
Live feed
·
PRReleasevia Quantisnow
AEON Biopharma Inc. logo

AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program

ByQuantisnow·Wall Street's wire, on your screen.
AEON· AEON Biopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AEON (AEON Biopharma Inc.) and more on Quantisnow.